Science TLDR

https://doi.org/10.1038/s41562-025-02267-6

https://doi.org/10.1080/19420862.2025.2532117

https://doi.org/10.1007/s11186-025-09635-1

https://doi.org/10.1038/s41598-025-03665-6

https://www.jstor.org/stable/2183914

Mixing it up a little with an episode covering 3 papers on the same topic. Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearancedoi:10.1016/j.addr.2008.04.012. A highly stable human single-domain antibody-drug conjugate exhibits superior penetration and treatment of solid tumorshttps://doi.org/10.1016/j.ymthe.2022.04.013. Influence of molecular size on tissue dis...

https://doi.org/10.1038/s41562-025-02196-4

doi: 10.1038/s41586-025-09053-4

https://doi.org/10.1038/s41586-025-08997-x

https://doi.org/10.1038/s41587-025-02654-4

DOI: 10.1056/NEJMoa2504747

https://www.nature.com/articles/s41586-025-08888-1

https://doi.org/10.1038/s41586-025-08852-z

DOI: 10.1038/s41586-025-08800-x

https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3003052

https://www.nature.com/articles/s42256-025-01005-x

https://www.biorxiv.org/content/10.1101/2025.02.19.639056v1

DOI: 10.1158/2643-3230.BCD-23-0258

DOI: 10.1038/s41467-025-56572-9 Key Points: - Introduces AlphaFold-Metainference, a new method combining AlphaFold predictions with physics simulations - Notable because AlphaFold was trained on structured proteins but shows surprising accuracy with disordered ones - Validated against experimental data from 11 different disordered proteins using SAXS (small-angle X-ray scattering) - Further valida...

DOI: 10.1038/s41590-023-01687-8 Key Points: - Research focuses on using engineered macrophages (CAR-iMACs) instead of typical CAR T cells to fight solid tumors - Started with iPSCs (induced pluripotent stem cells) which were differentiated into macrophages and engineered with CARs - Created two versions: - First generation with CD3ζ domain - Second generation with added TIR domain - Second generat...

DOI: 10.1056/NEJMoa2410965 Key Points: - Phase 3 trial testing obinutuzumab (anti-CD20 monoclonal antibody) + standard therapy vs placebo + standard therapy for lupus nephritis - Primary endpoint: Complete renal response at week 76 - Notable finding: 46.4% response with obinutuzumab vs 33.1% with placebo (13.4% improvement, p=0.02) Trial Design: - 271 adult patients with active lupus nephritis - R...

DOI: 10.1126/scitranslmed.adl6432 Key Points: The Research Problem: CAR-T cell therapy has been successful for blood cancers but faces challenges with solid tumors Major challenge: "On-target, off-tumor toxicity" where CAR-T cells attack healthy tissues Previous patient death case: HER2-targeted CAR-T cells attacked lung tissue due to HER2 expression on lung cells Study Focus: Target: EpCAM (epith...

DOI: 10.1038/s42256-024-00971-y Key Topics: - New deep learning model MUNIS for predicting CD8+ T-cell epitopes - Implications for vaccine development and personalized medicine - Real-world validation using Epstein-Barr virus (EBV) Background Science: - HLAI molecules display protein fragments (epitopes) on cell surfaces - CD8+ T-cells recognize foreign epitopes to trigger immune response - Tradit...

DOI: https://doi.org/10.1186/s40035-025-00465-w Key Discussion Points: 1. Overview of Current Landscape - Three FDA-approved second-generation antibodies: Aducanumab, Lecanemab, Donanemab - Lecanemab recently received traditional FDA approval - Represents validation of amyloid cascade hypothesis 2. Individual Antibody Profiles: Aducanumab - Derived from memory B cells of both healthy and cognitive...

DOI: 10.1126/science.adn9390 Key points: The Itch-Scratch Paradox Scratching is an evolutionarily conserved behavior but seems counterproductive as it worsens inflammation Research found scratching serves both harmful and beneficial purposes: Can exacerbate allergic skin conditions Helps protect against bacterial infections like S. aureus Provides insight into why scratching is pleasurable despite...